Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix Biopharma Corp.. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ("CAIAC") for the Company's remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. ("HIO"), for gross proceeds of PLN 6,700,000 (CAD $2,308,000). As announced on November 9, 2020, the Company signed a definitive agreement with CAIAC to purchase Helix's remaining holdings in HIO. About Helix BioPharma Corp. Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol "HBP". For more information: https://www.helixbiopharma.com
（以上内容由医药魔方AI生成）